FLT3-mutated Acute Myeloid Leukemia research hub

Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN

This study is looking at a new way to treat a type of blood cancer called FLT3-mutated Acute Myeloid Leukaemia. It combines standard treatments with a new medicine called venetoclax to see if it's safe and helps more people get better without the cancer coming back.